According to a new study, topical Janus Kinase (JAK) inhibitors become critical players in atopic dermatitis (AD) field. According to GlobalData, the early and late-stage pipelines are becoming increasingly crowded with JAK agents. According to the data and analytics firm, eight of the 98 pipeline drugs are JAKs, with six of them being topical formulations.
Ramla Salad, the pharma analyst at GlobalData, commented, “Janus Kinase inhibitors can combat AD at the immune system level due to their broad inhibitory effect. They are being developed in both oral and topical formulations, which target both mild-to-moderate and moderate-to-severe respectively. Thus, targeting an array of patient groups; younger patients will be able to tolerate the topical agents more especially for mild-to-moderate leading to better compliance. There may be a relatively small amount of JAKs on the market now but JAKs are set to revolutionise the AD space.”
Ruxolitinib’s closest competition is delgocitinib, a topical pan- Janus Kinase inhibitor developed by Danish company LEO Pharma for chronic hand eczema (CHE). Delgocitinib’s Phase IIb findings revealed a dose-dependent response to twice-daily dosages of 8mg/g and 20mg/g, with the maximum efficacy in adults with mild-to-severe CHE. According to IGA-CHE, over 40% of patients receiving either dose were symptom-free or nearly symptom-free by week 16 of treatment.